Posted by Michael Wonder on 14 Feb 2021
U.S. FDA approves Panzyga for the treatment of adults with chronic inflammatory demyelinating polyneuropathy
12 February 2021 - The first and only FDA approved intravenous immunoglobulin with two maintenance dosing options for chronic inflammatory demyelinating polyneuropathy.
Pfizer today announced that the U.S. FDA has approved the supplemental biologics license application for Panzyga (immune globulin intravenous [human] – ifas 10% liquid preparation) to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy.
